The present application describes novel hydantoin derivatives of formula (I): ##STR1##

or pharmaceutically acceptable salt or prodrug forms thereof, wherein L, Z0, R1, R4, R5, and R11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF- converting enzyme (TACE), aggrecanase, or a combination thereof.

 
Web www.patentalert.com

< Pharmaceutically active isoindoline derivatives

< Peptides for vaccinating against human CMV

> Inhibition of vacuolar proton ATPase activity and/or the modulation of acidic organelle function sensitizes cells to radiation, chemotherapy and biological agents

> Cyclic -amino acid derivatives as inhibitors of matrix metalloproteases and TNF-
~ 00260